Posted by Michael Wonder on 01 Nov 2022
Salvat Laboratories announces submission of new drug application to the US FDA for clobetasol nanoemulsion for treating inflammation and pain after ocular surgery
25 October 2022 - Salvat Laboratories today announced that it has submitted a new drug application to the US FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.
This submission comes after two successful Phase 3 clinical trials conducted between 2020 and 2021.
